• Robert Langer

      Co-founder

      Dr. Langer is the David H. Koch Institute Professor at Massachusetts Institute of Technology and a Co-Founder of Lyndra. Dr. Langer has written over 1,300 articles and has nearly 1,100 patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology and medical device companies leading to over 100 products in use or in clinical trials. He is the most cited engineer in history and has received over 220 major professional awards including the Queen Elizabeth Prize for Engineering in 2015, Priestly Medal in 2012, National Medal of Science in 2008, Charles Stark Draper Prize in 2002 (considered the equivalent of the Nobel Prize for engineers), and the Lemelson-MIT prize in 1998 for being "one of history's most prolific inventors in medicine".

      Dr. Langer is the David H. Koch Institute Professor at Massachusetts Institute of Technology and a Co-Founder of Lyndra. Dr. Langer has written over 1,300 articles and has nearly 1,100 patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology and medical device companies leading to over 100 products in use or in clinical trials. He is the most cited engineer in history and has received over 220 major professional awards including the Queen Elizabeth Prize for Engineering in 2015, Priestly Medal in 2012, National Medal of Science in 2008, Charles Stark Draper Prize in 2002 (considered the equivalent of the Nobel Prize for engineers), and the Lemelson-MIT prize in 1998 for being "one of history's most prolific inventors in medicine".

    • Gio Traverso

      Co-founder

      Dr. Traverso is an Instructor in Medicine and Associate Physician in the Division of Gastroenterology, Brigham and Women’s Hospital (BWH), Harvard Medical School. Dr. Traverso grew up in Peru, Canada and the United Kingdom. He received his BA from Trinity College, University of Cambridge, UK, and his PhD from the lab of Professor Bert Vogelstein at Johns Hopkins University. He subsequently completed medical school at the University of Cambridge, internal medicine residency at the Brigham and Women’s Hospital and his gastroenterology fellowship training at Massachusetts General Hospital, both at the Harvard Medical School. Dr. Traverso’s previous work focused on the development of novel molecular tests for the early detection of colon cancer. For his post-doctoral research he transitioned to the fields of chemical and biomedical engineering in the laboratory of Professor Robert Langer at the Massachusetts Institute of Technology (MIT) where he developed a series of novel technologies for drug delivery as well as physiological sensing via the gastrointestinal tract. Dr. Traverso’s was named one of the most promising innovators under 35 by the MIT Tech Review’s TR 35. He continues to collaborate closely with Professor Langer and is a Research Affiliate at MIT. His current research program is focused on developing the next generation of drug delivery systems to enable efficient delivery of therapeutics through the gastrointestinal tract.

      Dr. Traverso is an Instructor in Medicine and Associate Physician in the Division of Gastroenterology, Brigham and Women’s Hospital (BWH), Harvard Medical School. Dr. Traverso grew up in Peru, Canada and the United Kingdom. He received his BA from Trinity College, University of Cambridge, UK, and his PhD from the lab of Professor Bert Vogelstein at Johns Hopkins University. He subsequently completed medical school at the University of Cambridge, internal medicine residency at the Brigham and Women’s Hospital and his gastroenterology fellowship training at Massachusetts General Hospital, both at the Harvard Medical School. Dr. Traverso’s previous work focused on the development of novel molecular tests for the early detection of colon cancer. For his post-doctoral research he transitioned to the fields of chemical and biomedical engineering in the laboratory of Professor Robert Langer at the Massachusetts Institute of Technology (MIT) where he developed a series of novel technologies for drug delivery as well as physiological sensing via the gastrointestinal tract. Dr. Traverso’s was named one of the most promising innovators under 35 by the MIT Tech Review’s TR 35. He continues to collaborate closely with Professor Langer and is a Research Affiliate at MIT. His current research program is focused on developing the next generation of drug delivery systems to enable efficient delivery of therapeutics through the gastrointestinal tract.

    • Amy Schulman

      Co-Founder / Chief Executive Officer

      Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.

      Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.

    • Catherine B. Reynolds

      Member of the Board of Directors

      Catherine B. Reynolds is a successful entrepreneur and philanthropist. She brings to the world of philanthropy the same energy and entrepreneurial spirit that ensured her success in the realm of commerce. After graduating from Vanderbilt University, she started her business career as a CPA, and then became the Special Assistant to the Board Chairman of a Fortune 500 company. As the leader of two businesses, Mrs. Reynolds went on to launch a new and affordable way for Americans to finance a college education. She developed a privately-funded supplement to government student loan programs and created the securitization market for student loans on Wall Street. Through her vision and perseverance, millions of Americans have been able to attend the college of their choice. In only one decade, this creative approach to private educational financing revolutionized student lending and spawned a multibillion-dollar industry. Mrs. Reynolds now devotes her time and abilities primarily to philanthropic pursuits. She was selected by BusinessWeek magazine as one of the 50 most philanthropic living Americans and is the first self-made woman ever to make their list. Mrs. Reynolds has received honorary degrees from Georgetown University, Morehouse College and Willamette University, as well as New York University’s Gallatin Gold Medal. She was selected recently as Washingtonian of the Year, honoring “local heroes whose good works and generous spirits make Washington a great place to live and work.”

      Catherine B. Reynolds is a successful entrepreneur and philanthropist. She brings to the world of philanthropy the same energy and entrepreneurial spirit that ensured her success in the realm of commerce. After graduating from Vanderbilt University, she started her business career as a CPA, and then became the Special Assistant to the Board Chairman of a Fortune 500 company. As the leader of two businesses, Mrs. Reynolds went on to launch a new and affordable way for Americans to finance a college education. She developed a privately-funded supplement to government student loan programs and created the securitization market for student loans on Wall Street. Through her vision and perseverance, millions of Americans have been able to attend the college of their choice. In only one decade, this creative approach to private educational financing revolutionized student lending and spawned a multibillion-dollar industry. Mrs. Reynolds now devotes her time and abilities primarily to philanthropic pursuits. She was selected by BusinessWeek magazine as one of the 50 most philanthropic living Americans and is the first self-made woman ever to make their list. Mrs. Reynolds has received honorary degrees from Georgetown University, Morehouse College and Willamette University, as well as New York University’s Gallatin Gold Medal. She was selected recently as Washingtonian of the Year, honoring “local heroes whose good works and generous spirits make Washington a great place to live and work.”

    • Edmund Harrigan

      Member of the Board of Directors

      Edmund P. Harrigan, M.D. joined the pharmaceutical industry in 1990, following seven years in the private practice of neurology. He served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person organization in 80 countries that was responsible for managing regulatory interactions with global health agencies, as well as collecting, interpreting and reporting clinical safety data for more than 600 marketed products. Dr. Harrigan’s prior experience includes executive leadership roles at Sepracor, Neurogen and Karuna Pharmaceuticals as well as at Pfizer where he served as SVP, Head of Worldwide Business Development, SVP, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. He currently serves on the Board of Directors of Acadia Pharmaceuticals and Karuna Pharmaceuticals. Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts.

      Edmund P. Harrigan, M.D. joined the pharmaceutical industry in 1990, following seven years in the private practice of neurology. He served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person organization in 80 countries that was responsible for managing regulatory interactions with global health agencies, as well as collecting, interpreting and reporting clinical safety data for more than 600 marketed products. Dr. Harrigan’s prior experience includes executive leadership roles at Sepracor, Neurogen and Karuna Pharmaceuticals as well as at Pfizer where he served as SVP, Head of Worldwide Business Development, SVP, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. He currently serves on the Board of Directors of Acadia Pharmaceuticals and Karuna Pharmaceuticals. Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts.

    • Amy Schulman

      Co-Founder / Chief Executive Officer

      Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.

      Amy Schulman is a co-founder and Chief Executive Officer of Lyndra, Inc. and a Partner at Polaris Partners. Amy joined Polaris in 2014 and immediately assumed the role of Chief Executive Officer of Arsia Therapeutics, which was subsequently acquired by Eagle Pharmaceuticals in 2016. In 2015 she co-founded and joined Lyndra, Inc. as Chief Executive Officer. Prior to joining Polaris, Amy was Executive Vice President and General Counsel of Pfizer, Inc. where she was responsible for leading Pfizer’s Consumer Healthcare Business. Amy has received numerous awards including Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and currently serves as Executive Chair of SQZ Biotech and Olivo Labs, LLC, and is on the Boards of Directors of Alnylam Pharmaceuticals, Blue Buffalo, Ironwood Pharmaceuticals, and the Whitehead Institute.

    • Andrew Bellinger

      Co-founder / Chief Scientific Officer

      Andrew co-founded Lyndra and serves as its Chief Scientific Officer. He studied biophysics at Princeton and applied mathematics at NYU. He received a PhD from Columbia University studying mechanisms of calcium signaling in skeletal and cardiac muscle while developing novel therapies to treat muscular dystrophies. He has an MD from the College of Physicians and Surgeons at Columbia University and completed clinical training in internal medicine at the University of California, San Francisco and in cardiovascular disease at Brigham and Women's Hospital and Massachusetts General Hospital. He is board certified in internal medicine and in cardiovascular medicine and continues to see patients at Brigham and Women’s Hospital. He led the development of the original Lyndra drug delivery technology while working at MIT with Dr. Robert Langer.

      Andrew co-founded Lyndra and serves as its Chief Scientific Officer. He studied biophysics at Princeton and applied mathematics at NYU. He received a PhD from Columbia University studying mechanisms of calcium signaling in skeletal and cardiac muscle while developing novel therapies to treat muscular dystrophies. He has an MD from the College of Physicians and Surgeons at Columbia University and completed clinical training in internal medicine at the University of California, San Francisco and in cardiovascular disease at Brigham and Women's Hospital and Massachusetts General Hospital. He is board certified in internal medicine and in cardiovascular medicine and continues to see patients at Brigham and Women’s Hospital. He led the development of the original Lyndra drug delivery technology while working at MIT with Dr. Robert Langer.

    • Robert Crane

      Chief Financial Officer

      Robert Crane has been CFO of over 20 healthcare companies in the therapeutic, medical device and diagnostic fields including Sirtris, I-Stat, Circe Biomedical, Taris Biomedical, MicroCHIPS and GI Dynamics. Bob was also CFO for the turnaround and sale of Seragen and was the Chairman of American Bicycle Group, a market leader in titanium and triathlon bicycles. Prior to that, Bob was a partner at Montgomery Ventures, a venture capital firm investing in healthcare and technology. Bob has a degree in mechanical engineering from MIT and an MBA from Stanford.

      Robert Crane has been CFO of over 20 healthcare companies in the therapeutic, medical device and diagnostic fields including Sirtris, I-Stat, Circe Biomedical, Taris Biomedical, MicroCHIPS and GI Dynamics. Bob was also CFO for the turnaround and sale of Seragen and was the Chairman of American Bicycle Group, a market leader in titanium and triathlon bicycles. Prior to that, Bob was a partner at Montgomery Ventures, a venture capital firm investing in healthcare and technology. Bob has a degree in mechanical engineering from MIT and an MBA from Stanford.

    • Raymond Knox

      Senior Vice President of Manufacturing

      Prior to joining Lyndra in 2016 Ray has worked in the Medical device industry for 28 years in the design, development and manufacturing of medical devices. Ray was VP of Manufacturing at 480 Biomedical, developing a novel bioresorbable drug eluting scaffold for the SFA. Ray has worked as the vice president of quality assurance and clinical quality at Boston Scientific, where he was responsible for the development of quality systems for the clinical organization, re-creation of post-market surveillance processes and development of analytical infrastructure for the successful product TAXUS®. Additionally, Ray has worked with Ximedica, Becton Dickinson, USCI, and Medtronic. His experience spans large-scale automated manufacturing, highly specialized research and development prototypes, innovative process development, characterization and process validation. Ray has successfully released 16, class 2 & 3, medical devices products in the US. Ray holds a bachelor’s degree in mechanical engineering from University College Dublin and a master’s degree in business administration from Assumption College.

      Prior to joining Lyndra in 2016 Ray has worked in the Medical device industry for 28 years in the design, development and manufacturing of medical devices. Ray was VP of Manufacturing at 480 Biomedical, developing a novel bioresorbable drug eluting scaffold for the SFA. Ray has worked as the vice president of quality assurance and clinical quality at Boston Scientific, where he was responsible for the development of quality systems for the clinical organization, re-creation of post-market surveillance processes and development of analytical infrastructure for the successful product TAXUS®. Additionally, Ray has worked with Ximedica, Becton Dickinson, USCI, and Medtronic. His experience spans large-scale automated manufacturing, highly specialized research and development prototypes, innovative process development, characterization and process validation. Ray has successfully released 16, class 2 & 3, medical devices products in the US. Ray holds a bachelor’s degree in mechanical engineering from University College Dublin and a master’s degree in business administration from Assumption College.

    • Ellie McGuire

      Head of Business Development

      Ellie has held positions and consulted in business development, operations, and strategy for multiple early life science companies including Arsia Therapeutics, SQZ Biotech, and Xtuit Pharmaceuticals. She brings experience in partnership management, operations and fundraising to the team. Ellie graduated from Colby College Magna Cumme Laude and as a member of Phi Beta Kappa. Following her collegiate education, Ellie attended Tuck School of Management Business Bridge Program.

      Ellie has held positions and consulted in business development, operations, and strategy for multiple early life science companies including Arsia Therapeutics, SQZ Biotech, and Xtuit Pharmaceuticals. She brings experience in partnership management, operations and fundraising to the team. Ellie graduated from Colby College Magna Cumme Laude and as a member of Phi Beta Kappa. Following her collegiate education, Ellie attended Tuck School of Management Business Bridge Program.

    • Jessica Ballinger

      Vice President of Reimbursment and Strategic Alliances

      Jessica is a global drug and medical device executive with a proven ability to identify and respond to unmet patient needs and market opportunities. Prior to joining Lyndra, Jessica led organizations at Pfizer and Biogen focused on product design and commercialization, leveraging her strong technical background with expert organizational skills. Her passion for the patient drives innovative solutions and establishes or revitalizes value for patients and payers through new product launches. She has delivered new products in brands such as Genetropin®, Somatotropin®, Xalatan®, Avonex®, Plegridy®, Zynbryta®, Eloctate®, and Alprolix® and overseen product design in therapeutic areas such as neuroscience, cardiovascular and metabolism, immunology, allergy and respiratory, hematology, and rare diseases.

      Jessica is a global drug and medical device executive with a proven ability to identify and respond to unmet patient needs and market opportunities. Prior to joining Lyndra, Jessica led organizations at Pfizer and Biogen focused on product design and commercialization, leveraging her strong technical background with expert organizational skills. Her passion for the patient drives innovative solutions and establishes or revitalizes value for patients and payers through new product launches. She has delivered new products in brands such as Genetropin®, Somatotropin®, Xalatan®, Avonex®, Plegridy®, Zynbryta®, Eloctate®, and Alprolix® and overseen product design in therapeutic areas such as neuroscience, cardiovascular and metabolism, immunology, allergy and respiratory, hematology, and rare diseases.

    • Joan Dee Resnicow

      Head of Operations and Human Resources

      Joan Resnicow has held positions in human resources, finance and operations at development stage life science companies including GI Dynamics and MicroCHIPS. She brings experience in establishing and building human resources, finance, facilities and IT functions. Joan studied at The New England Conservatory and the Royal Academy of Music and was graduated from Tufts University.

      Joan Resnicow has held positions in human resources, finance and operations at development stage life science companies including GI Dynamics and MicroCHIPS. She brings experience in establishing and building human resources, finance, facilities and IT functions. Joan studied at The New England Conservatory and the Royal Academy of Music and was graduated from Tufts University.

  • The Lyndra team encompasses exceptional individuals representing a diverse skill set including chemical engineers, process engineers, formulation scientists, polymer scientists, pharmacology, toxicology and analytical professionals, operational and business development experts. Our growing team is well positioned to solve complex problems and build a company that delivers lasting value to its stakeholders.

    • Jackie Schumacher

      Vice President of Regulatory

      Prior to joining Lyndra, Jackie spent most of her 30+ year career in Pharmaceutical Sciences within Pfizer, starting as an analytical chemist following by a long tenure within the Regulatory CMC organization. She has led teams to develop successful global CMC registration strategies for new small molecules, product enhancements, inhalation and injectable products. Jackie also held several business-facing/commercial roles, including regulatory leadership within the nascent Established Products Sterile Injectables organization and later as Portfolio Optimization and Strategy Leader; facilitating a matrixed team of colleagues tasked with radically optimizing the value of the 600+ molecule portfolio. In addition to her Pfizer-based experiences, she has chaired an industry trade association, IPAC-RS, focused on strategic pharmaceutical development and regulatory objectives for orally inhaled and nasal drug products; serving as the leader of several of its working groups. Jackie earned her B.A. degrees in Chemistry and Classical Studies from Hamilton College.

      Prior to joining Lyndra, Jackie spent most of her 30+ year career in Pharmaceutical Sciences within Pfizer, starting as an analytical chemist following by a long tenure within the Regulatory CMC organization. She has led teams to develop successful global CMC registration strategies for new small molecules, product enhancements, inhalation and injectable products. Jackie also held several business-facing/commercial roles, including regulatory leadership within the nascent Established Products Sterile Injectables organization and later as Portfolio Optimization and Strategy Leader; facilitating a matrixed team of colleagues tasked with radically optimizing the value of the 600+ molecule portfolio. In addition to her Pfizer-based experiences, she has chaired an industry trade association, IPAC-RS, focused on strategic pharmaceutical development and regulatory objectives for orally inhaled and nasal drug products; serving as the leader of several of its working groups. Jackie earned her B.A. degrees in Chemistry and Classical Studies from Hamilton College.

    • Susan Low

      Head of Pharmacology, Toxicology, and Biology

      Susan has experience in pharmacology, toxicology and in vitro biology in the areas of molecular endocrinology, viral RNA stability, hemophilia and oncology. Susan led pharmacology, toxicology and biology efforts at BIND Therapeutics in the pursuit of developing and evaluating polymeric nanoparticles for oncology. Prior to her position at BIND, she developed Fc-fusion protein technology at Syntonix Pharmaceuticals with a particular focus on pharmacology and toxicology of FIX-Fc and FVIII-Fc fusion proteins for the treatment of hemophilia. Susan held post-doctoral positions at Brigham and Women’s Hospital, Harvard Medical School, and MIT after receiving her PhD in biology with a focus on molecular endocrinology from the University of Edinburgh.

      Susan has experience in pharmacology, toxicology and in vitro biology in the areas of molecular endocrinology, viral RNA stability, hemophilia and oncology. Susan led pharmacology, toxicology and biology efforts at BIND Therapeutics in the pursuit of developing and evaluating polymeric nanoparticles for oncology. Prior to her position at BIND, she developed Fc-fusion protein technology at Syntonix Pharmaceuticals with a particular focus on pharmacology and toxicology of FIX-Fc and FVIII-Fc fusion proteins for the treatment of hemophilia. Susan held post-doctoral positions at Brigham and Women’s Hospital, Harvard Medical School, and MIT after receiving her PhD in biology with a focus on molecular endocrinology from the University of Edinburgh.

    • Stephen Zale

      Scientific Fellow

      Stephen Zale is Scientific Fellow at Lyndra. Previously, Stephen was Vice President of Development and founding scientist at BIND Therapeutics, and was Vice President of Injectable Products R&D at Alkermes where he led the group responsible for formulating Alkermes' biodegradable polymer-based microsphere products, including Risperdal Consta, Vivitrol and Bydureon. Stephen received a Ph.D. in Biochemical Engineering and a B.S. in Chemistry, both from MIT.

      Stephen Zale is Scientific Fellow at Lyndra. Previously, Stephen was Vice President of Development and founding scientist at BIND Therapeutics, and was Vice President of Injectable Products R&D at Alkermes where he led the group responsible for formulating Alkermes' biodegradable polymer-based microsphere products, including Risperdal Consta, Vivitrol and Bydureon. Stephen received a Ph.D. in Biochemical Engineering and a B.S. in Chemistry, both from MIT.